A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 417 participants.

Also called NCT05171075

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 417 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05171075
  • EudraCT 2021-003085-12
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Austria, Canada, China, Czechia, France, Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05171075. Randomized; single masking; primary purpose treatment. Start 2022-09-27 (actual); primary completion 2026-04-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Acronym
MAGNOLIA
Condition
Venous Thromboembolism
Condition
Deep Venous Thrombosis
Intervention (Biological)
Abelacimab
Intervention (Drug)
Dalteparin
Lead sponsor
Anthos Therapeutics, Inc. (class: industry)
Collaborator
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05171075
Content hash
7e6a81c29b4855434772cf54f08aaba626d040d6d2b7ca481ccd6e5713c35fc8